Claire Bonfils

Claire Bonfils has a diverse work experience in the field of biotechnology and research. Claire is currently working as a Senior Scientist at Congruence Therapeutics since August 2022. Prior to this, they were employed at KisoJi Biotechnology as a Senior Research Associate from November 2016 to August 2022. Claire also worked at enGene Inc as a Research Associate from January 2014 to November 2016. Their extensive experience also includes working at MethylGene (Mirati Therapeutics) as a Senior Research Scientist from July 1997 to December 2013, where they played a crucial role in the development and characterization of the multi-target RTK inhibitor Glesatinib. Before that, Claire was a Research Assistant at Concordia University from 1992 to 1997, where they contributed to the study of ribonucleotide reductase small subunit activity during D. discoideum development.

Claire Bonfils has a diverse education history. Claire obtained their M.Sc. in Molecular Biology from McGill University in 1992. Prior to that, they completed their B.Sc. in Biology with a focus on microbiology at Université de Montréal in 1987. Their education journey traces back to their completion of a Baccalauréat in C (Math-physique) from Collège Marie-de-France in 1984. In addition to their formal education, Claire also pursued personal development and communication skills through Toastmasters, though specific details about the duration and degree obtained are not provided.